Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Finlabo SIM Spa
$10.00
Provider: Reuters Investment Profile
$20.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Bayer AG Receives Approval For EYLEA In Next Indication In Europe


Thursday, 29 Aug 2013 06:18am EDT 

Bayer AG announced that EYLEA (aflibercept solution for injection) has been approved by the European Commission for the treatment of visual impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (CRVO). The results of the two phase III studies were encouraging with the majority of patients with Macular Edema secondary to Central Retinal Vein Occlusion experiencing a significant improvement in visual acuity with EYLEA. EYLEA is already approved in the United States for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) and for Macular Edema following CRVO. EYLEA has also been approved in Europe, Japan, Australia, and several other countries for use in wet AMD and in selected countries in South America for Macular Edema following CRVO. 

Company Quote

95.41
-2.28 -2.33%
15 Aug 2014